Literature DB >> 12067927

Patients with acute coronary syndrome should start a statin while still in hospital.

C G Isles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12067927      PMCID： PMC1767166          DOI： 10.1136/heart.88.1.5

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  16 in total

1.  Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

Authors:  D M Pickin; C J McCabe; L E Ramsay; N Payne; I U Haq; W W Yeo; P R Jackson
Journal:  Heart       Date:  1999-09       Impact factor: 5.994

2.  The implications of the National Service Framework for coronary heart disease.

Authors:  A S Wierzbicki
Journal:  J R Soc Promot Health       Date:  2000-09

3.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

4.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).

Authors:  G C Fonarow; A Gawlinski; S Moughrabi; J H Tillisch
Journal:  Am J Cardiol       Date:  2001-04-01       Impact factor: 2.778

5.  Early statin treatment following acute myocardial infarction and 1-year survival.

Authors:  U Stenestrand; L Wallentin
Journal:  JAMA       Date:  2001 Jan 24-31       Impact factor: 56.272

6.  Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality.

Authors:  J B Muhlestein; B D Horne; T L Bair; Q Li; T E Madsen; R R Pearson; J L Anderson
Journal:  Am J Cardiol       Date:  2001-02-01       Impact factor: 2.778

7.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.

Authors: 
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

8.  Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

Authors:  G C Fonarow; W J French; L S Parsons; H Sun; J A Malmgren
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

9.  Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).

Authors:  H R Arntz; R Agrawal; W Wunderlich; L Schnitzer; R Stern; F Fischer; H P Schultheiss
Journal:  Am J Cardiol       Date:  2000-12-15       Impact factor: 2.778

10.  Age, sex and practice variations in the use of statins in general practice in England and Wales.

Authors:  A Majeed; K Moser; R Maxwell
Journal:  J Public Health Med       Date:  2000-09
View more
  3 in total

1.  The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention.

Authors:  Jessica M Ma; Cynthia A Jackevicius; Uchenwa Genus; Vladimir Dzavik
Journal:  Can J Cardiol       Date:  2006-04       Impact factor: 5.223

2.  The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease: a cohort study.

Authors:  Charmaine A Cooke; Susan A Kirkland; Ingrid S Sketris; Jafna Cox
Journal:  BMC Health Serv Res       Date:  2009-11-04       Impact factor: 2.655

3.  How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England.

Authors:  Paul R Ward; Peter R Noyce; Antony S St Leger
Journal:  Int J Equity Health       Date:  2007-03-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.